MYLK Antibody (MLJ-7): sc-69876

MYLK Antibody (MLJ-7) is a mouse monoclonal IgG1 antibody that detects myosin light chain kinase (MYLK) in human samples through western blotting (WB). MYLK is a crucial enzyme that plays a significant role in muscle contraction by phosphorylating myosin regulatory light chains, which facilitates the interaction between myosin and actin filaments, ultimately leading to contractile activity. This process is vital not only in skeletal and cardiac muscles but also in smooth muscle tissues, where MYLK isoforms contribute to various physiological functions, including vascular tone regulation and gastrointestinal motility. The MYLK gene encodes multiple isoforms, including those specific to smooth muscle and non-muscle tissues, as well as telokin, a smaller isoform that stabilizes unphosphorylated myosin filaments, thereby influencing muscle contraction dynamics. Additionally, MYLK is subject to regulation by p21-activated kinases (PAKs), with PAK1′s interaction leading to a decrease in MYLK activity and subsequent myosin light chain phosphorylation, highlighting the importance of MYLK in cellular signaling pathways and muscle physiology. Anti-MYLK antibody (MLJ-7) is an essential tool for researchers investigating muscle function and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MYLK Antibody (MLJ-7) References:

1. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.  |  Tan, X. and Chen, M. 2014. Tumour Biol. 35: 12189-200. PMID: 25179839
2. ROCK2 and MYLK variants under hypobaric hypoxic environment of high altitude associate with high altitude pulmonary edema and adaptation.  |  Pandey, P., et al. 2015. Appl Clin Genet. 8: 257-67. PMID: 26586960
3. Two novel MYLK nonsense mutations causing thoracic aortic aneurysms/dissections in patients without apparent family history.  |  Luyckx, I., et al. 2017. Clin Genet. 92: 444-446. PMID: 28401540
4. Circular RNA Myosin Light Chain Kinase (MYLK) Promotes Prostate Cancer Progression through Modulating Mir-29a Expression.  |  Dai, Y., et al. 2018. Med Sci Monit. 24: 3462-3471. PMID: 29798970
5. Androgen receptor variant 12 promotes migration and invasion by regulating MYLK in gastric cancer.  |  Xia, N., et al. 2019. J Pathol. 248: 304-315. PMID: 30737779
6. circRNA MYLK Accelerates Cervical Cancer via Up-Regulation of RHEB and Activation of mTOR Signaling.  |  Chen, R., et al. 2020. Cancer Manag Res. 12: 3611-3621. PMID: 32547198
7. Circular RNA MYLK Promotes Glycolysis and Proliferation of Non-Small Cell Lung Cancer Cells by Sponging miR-195-5p and Increasing Glucose Transporter Member 3 Expression.  |  Xiong, S., et al. 2020. Cancer Manag Res. 12: 5469-5478. PMID: 32753964
8. Using machine learning method to identify MYLK as a novel marker to predict biochemical recurrence in prostate cancer.  |  Qiao, P., et al. 2021. Biomark Med. 15: 29-41. PMID: 33427497
9. Correction: LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGF R-2 signaling pathway in hepatocellular carcinoma.  |  Teng, F., et al. 2023. J Exp Clin Cancer Res. 42: 257. PMID: 37775828
10. Aortic dissection in a young male with persistent ductus arteriosus and a novel variant in MYLK.  |  Boelman, MB., et al. 2024. Am J Med Genet A. 194: e63458. PMID: 37921548

The preferred MYLK antibody is MYLK Antibody (A-8): sc-365352.